Clinical Study Results of Desoximetasone Spray, 0.25% in Moderate to Severe Plaque Psoriasis

December 2013 | Volume 12 | Issue 12 | Original Article | 1404 | Copyright © December 2013

Leon Kircik MD,a,b,c Mark G. Lebwohl MD,c James Q. Del Rosso DO,d
Jerry Bagel MD,eLinda Stein Gold MD,f Jonathan S. Weiss MDg

aDepartment of Dermatology, Indiana University School of Medicine, Indianapolis, IN
bPhysicians Skin Care, PLLC, Louisville, KY
cDepartment of Dermatology, Mount Sinai School of Medicine, New York, New York
dDepartment of Dermatology, Touro University College of Osteopathic Medicine, Henderson, NV
ePsoriasis Treatment Center of Central New Jersey, East Windsor, NJ
fDirector of Dermatology, Clinical Research and Division Head of Dermatology, Henry Ford Health System, Detroit and West Bloomfield, Michigan
gGwinnett Clinical Research Center, Snellville, Georgia

table 5
What can be gleaned from the study design that may potentially be clinically relevant? Super-potent TCS remain as a central component of the treatment armamentarium for plaque psoriasis including all ranges of severity.9-12 However, judicious use with an appreciation of both their therapeutic benefits and limitations is vital in order to achieve successful treatment outcomes, including understanding of how to manage vehicle selection, potency, and the specific disease state being treated. In the case of plaque psoriasis, dermatology providers have learned to utilize agents with higher potency ranking to optimize initial control and then to adjust treatment based on the clinical response.9-12
As many subjects with >=10% BSA are considered candidates for systemic therapies such as biologic agents, the subject may be transitioned if necessary to such a therapy after completion of the initial course with desoximetasone spray 0.25% used for up to 4 weeks.4,9 Additionally, the spray vehicle is an invaluable tool for the treatment of large body surface, as well as hairbearing areas such as the scalp and difficult to reach areas. More specifically, twice daily application of desoximetasone spray 0.25% was shown to be significantly superior to the vehicle and well-tolerated. There were no statistically significant differences between the adverse events reported in active and vehicle arms and no burning or stinging was reported.


Desoximetasone spray 0.25% is a super-potent TCS formulation that has the potential based on clinical studies to be a valuable addition to the treatment armamentarium for plaque psoriasis. Ultimately, it is important that safety considerations be taken into account with all therapies, thus necessitating education on the proper use and application, frequency, duration, and followup when desoximetasone spray 0.25% is prescribed.


The authors would like to acknowledge the clinical investigators who participated in the desoximetasone spray, 0.25% pivotal studies including John Fitzgerald Adams MD, Barbara Bopp MD, Robert Brown MD, Alicia Bucko DO JD, Michael Buhalo MD, Zoe Draelos MD, Scott Geunther MD,